Summary
Cardinal Health Inc. (CAH) reported its second quarter fiscal year 2020 results, highlighting a 5% increase in total revenue to $39.7 billion, driven primarily by growth in its pharmaceutical distribution and specialty solutions businesses. While revenue showed positive momentum, the company's GAAP operating earnings were significantly impacted by a $96 million charge related to a voluntary surgical gown recall and a substantial $5.63 billion pre-tax charge for the estimated liability associated with opioid litigation. Despite these significant charges, the company's non-GAAP operating earnings saw a modest 1% increase for the quarter and a 4% increase for the six-month period, reflecting underlying operational performance that excludes these extraordinary items. Investors should note the company's proactive approach to managing its balance sheet, including debt repayments and share repurchases, alongside maintaining a strong cash position. The opioid litigation settlement framework, while substantial, provides a path toward resolution, though uncertainties remain regarding final terms and future liabilities related to treatment medications and program changes. The surgical gown recall, while impacting current quarter results, is not expected to materially impact the long-term goodwill of the Medical Unit at this time. The company reiterated its belief in having adequate capital resources to meet its obligations, including potential opioid settlement payments.
Financial Highlights
46 data points| Revenue | $39.73B |
| Cost of Revenue | $38.02B |
| Gross Profit | $1.71B |
| SG&A Expenses | $1.16B |
| Operating Income | $334.00M |
| Interest Expense | $63.00M |
| Net Income | $220.00M |
| Shares Outstanding (Basic) | 292.00M |
| Shares Outstanding (Diluted) | 294.00M |
Key Highlights
- 1Total revenue increased by 5% to $39.7 billion for the three months ended December 31, 2019, and by 6% to $77.1 billion for the six months ended December 31, 2019, driven by pharmaceutical distribution and specialty solutions.
- 2GAAP operating earnings declined 34% for the quarter and were a loss of $4.93 billion for the six months due to significant charges, including $96 million for surgical gown recalls and a $5.63 billion pre-tax charge for opioid litigation.
- 3Non-GAAP operating earnings increased 1% to $646 million for the quarter and 4% to $1.22 billion for the six months, demonstrating resilience in core operations.
- 4Non-GAAP diluted EPS rose 18% to $1.52 for the quarter, indicating improved profitability on an adjusted basis.
- 5The company agreed in principle to a global settlement framework for opioid lawsuits, involving a cash component of up to $5.56 billion over eighteen years, along with other commitments.
- 6A voluntary recall of surgical gowns resulted in a $96 million charge in the quarter, with ongoing supply chain impacts anticipated.
- 7Cash and equivalents decreased to $1.7 billion from $2.5 billion, with $44 million in net cash provided by operating activities during the first six months of the fiscal year, while capital was deployed for debt repayment, share repurchases, and dividends.